Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients-Reference-Cited by-同舟云学术

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

Published:2023-01-31 Issue:2 Volume:7 Page:e829
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Ocio Enrique M.¹,Bringhen Sara²,Martinez-Lopez Joaquin³,San-Miguel Jesus⁴,Oliva Stefania²,Rodriguez-Otero Paula⁴,Le Roux Nadia⁵,Dong Yvonne⁶,Doroumian Severine⁷,Macé Sandrine⁸,Mateos Maria-Victoria⁹

Affiliation:

1. Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain

2. SSD Clinical Trials in Onco-Ematologia e Myeloma Multiplo, AOU Città della Salute e della Scienza di Torino, Italy

3. Hematology, Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense de Madrid, Spain

4. University Clinic of Navarra, CCUN, Center for Applied Medical Research (CIMA), IDISNA, CIBERONC, Pamplona, Spain

5. Altran, Neuilly Sur Seine, France, on behalf of Sanofi

6. Sanofi, Bejing, China

7. Sanofi, Montpellier, France

8. Sanofi, Translational Medicine, Chilly-Mazarin, France

9. University Hospital of Salamanca and Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain

Publisher

Wiley

Subject

Hematology

Reference13 articles.

1. Management of multiple myeloma in the newly diagnosed patient.;Mateos;Hematology Am Soc Hematol Educ Program,2017

2. The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.;Bonello;Pharmaceuticals (Basel),2020

3. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.;Bringhen;Haematologica,2013

4. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.;Jimenez-Zepeda;Ann Hematol,2017

5. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.;Mai;Leukemia,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-CD38 monoclonal antibody impairs CD34+mobilization and affects clonogenic potential in multiple myeloma patients;BLOOD TRANSFUS-ITALY;2024

2. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-06